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Introduction. Airway infl ammation is a common feature of many diseases. Its repercussions can be discovered in 
many aspects of the disease, therefore fi nding the biomarker or combination of biomarkers to defi ne it continues to 
be challenging.
Th e scientifi c material and methods used are the review of current literature data, controversies, discordances and 
peculiarities of respiratory tract infl ammation and biomarkers capable to assess it.
Th e results are centered on those biomarkers capable to capture infl ammation from as many angles as possible, with 
impact not only on the pathogenesis of the disease but also with clinical, evolution, therapeutic and monitoring impli-
cations.
Conclusions. For airway infl ammation many biomarkers are useful, some defi ne the disease as a whole, some are 
defi ning for certain aspects or endotypes. Th e winning combination proposed by many authors appears to be a panel 
of biomarkers which captures as many aspects as possible for each entity, but is usually diffi  cult to fi nd.
Tables and fi gures
Table 1. Types of biomarkers assessing the airway infl ammation
Table 2 Types of interleukines and their connection with airway infl ammation
Figure 1 Lymphocite T polarization: type 1 and type 2 immune responses
Introduction
Despite all its negative traits, the infl ammation is a 
remarkable reaction of the body to injurious factors, 
designed to restore homeostasis. Th e infl ammatory 
process is very complex, implicating numerous cells, 
mediators, immune system and regulatory pathways. 
Two forms of infl ammation are classically described, 
acute and chronic, based on its duration. Chronic infl am-
mation lasts more than 4 weeks and is usually preceded 
by an acute form. Th ese two forms may also coexist. In 
order to keep a prolonged duration, the infl ammatory 
response lingers and the injurious agent acts continu-
ously. Chronic infl ammation includes several events, 
involving recruitment of cells and chronic cellular infi l-
trate as a result, tissue destruction, resolution or scarring 
in the attempt to repair the damaged tissue. Repair is a 
very complex process, far from perfect, involving prolif-
eration of the fi broblasts and fi brosis, collagen deposition 
and remodeling of the tissues.
Biomarkers to defi ne both acute and chronic infl amma-
tion are continually discovered. Th ese biomarkers are far 
more important for chronic infl ammation, where they 
defi ne many endotypes for each disease and have impact 
on its evolution, treatment and prognosis. 
Chronic airway diseases are defi ned by chronic local 
infl ammation and a state of low-grade systemic infl am-
mation.
Biomarker – defi nition
According to the Food and Drug Administration (FDA), 
a valid biomarker is defi ned as “measured in an analyt-
ical test system with well-established performance char-
acteristics and for which there is an established scientifi c 
framework or body of evidence that elucidates the phys-
iologic, toxicologic, pharmacologic, or clinical signifi -
cance of the test results.” [1]
Classifi cation of biomarkers
Molecular biomarkers can be classifi ed based on many 
criteria, such as objective, source, origin, chemical 
composition, genetics and molecular biology.
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Based on their objective, biomarkers can be: diagnostic 
biomarkers, prognostic biomarkers and biomarkers for 
monitoring clinical response.
If the the measured parameter is taken into consideration, 
the biomarkers can be divided into three distinct groups:
– Biomarkers of exposure – measuring in an internal 
compartment an exogenous molecule or metabolite 
resulting from an extrinsic exposure. Th ey assess the 
exposure and are useful for biomonitoring.
– Biomarkers of eff ect – physical, biochemical, mole-
cular parameters correlated with a certain dysfunc-
tion or disease; 
– Biomarkers of susceptibility – refers to the intrinsic 
ability of the body to react in a predictable way to a 
extrinsic exposure, refl ect the features that make an 
organism more susceptible.[8]
Biomarkers are classifi ed in three categories, based on 
genetics and molecular biology methods:
– Type 0 – natural history biomarker – correlates the 
natural history of the disease with the clinical features.
– Type 1- drug activity biomarker- which capture the 
eff ects of an action, act as marker of responsiveness to 
the treatment and can be further divided into effi  cacy 
biomarkers (therapeutic eff ects of a drug), mecha-
nism biomarkers (mechanism of action of a drug) 
and toxicity biomarkers (toxicological eff ects of a 
drug)
– Type 2 – surrogate marker, indicating a risk. [5]
Sources of biomarkers correlated to airway infl ammation 
are very divers. Some of them are easier to approach, 
others are reserved only to selected cases.
– Bioptic fragments obtained by bronchoscopy are 
considered the gold standard but diffi  cult to obtain, 
costly, therefore not accessible;
– Bronchoalveolar lavage is reliable for the underlying 
infl ammatory process and obtained with minimum 
invasiveness; 
– Induced sputum is also reliable for the infl ammation 
and noninvasive, but diffi  cult to obtain for pediatric 
patient;
– Exhaled breath condensate contains a group of 
biomarkers and great variability in composition;
– Serum is a rich source of divers biomarkers and reli-
able for the disease;
– Urine has limited value for airway infl ammation, 
even though many biomarkers have been discovered 
in the past years.
Origin of biomarkers can be the resident cells of the 
lung and airway or the cells infi ltrating at infl amma-
tion site. Th e cells themselves and their products can be 
considered biomarkers. Some of the biomarkers assess 
the infl ammation overall while others give information 
about certain aspects, closely related with the underlying 
immune processes. 
Biomarkers of chronic airway infl ammation
Th ere is a large variety of biomarkers assessing the airway 
infl ammation. Th e panel includes cellular biomarkers, 
proteic molecules, lipidic derivates, oxidative stress 
products, enzymes, hormones, receptors, nucleic acids 
in diff erent combinations and evaluated in varied condi-
tions such as: stable disease, exacerbation, association of 
infection. 
Biomarkers that assess globally the infl ammatory process 
are acute phase reactants- fi brinogen, ferritin, “C” reac-
tive protein, complement, haptoglobin, serum amyloid A, 
plasminogen and white blood cells. Th ey give a measure 
to the infl ammation, without giving information of the 
immune dyregulations underlying it. Together with other 
biomarkers can build an endotype of a disease. Among 
these biomarkers hs-CRP, serum amyloid A, haptoglobin 
were highly studied.
Table 1. Types of biomarkers assessing the airway infl ammati on [1,11,24]
Source Type of biomarker
Bronchoalveolar lavage Cells:macrophages, neutrophils, eosinophils, lymphocites,epithelial cells,
Proteic molecules: cytokines (IL-1RA, IL-1α, IL-1β, IL-2Rα, IL-5, IL-6, IL-7, IL-8, IL-37, G-CSF, 
RANTES ). Enzymes: matrix metalloprotease 9 (MMP-9)
Induced sputum Cells: Eosinophils, neutrophils, NK, lymphocites
Proteic molecules: cytokines, eosinophil cationic proteins, granulocyte macrophage colony stimu-
lator factor, neurokinin A, claudins, HMGB1
Lipidic derivates: Cys-LT, lipoxin A4, isoprostan
Oxidative stress products: NO derivates, aldehides. Receptors: IL17R
Enzymes: plasminogen activator, MMPs, tissue inhibitors of metalloproteinase (TIMPs), ADAMTS, 
ADAM-8, ADAM-7, ADAM-33 
Exhaled breath condensate Oxidative stress products: eNO, hydrogen peroxide, nitric oxides 
Lipidic derivates: LT, PGE2,TXB2, Cys-LT, isoprostanes 
Proteic molecules: cytokines, endotelin-1. Nucleic acids: micro-ribonucleic acid (miRNA). En-
zymes: matrix metalloprotease 9 (MMP-9)
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Serum Cells: Eosinophils, IgE total and specifi c, 
Proteic molecules: cytokines, eosinophil cationic protein, eosinophil- derived neurotoxin, surfac-
tant protein D, fi brinogen, hsCRP, growth factors- fi broblast, hepatocyte, stem cell, periostin, YKL-
40, leptin, lactoferin, desmosine, natriuretic peptide type b, copeptin, DDP-4, defensins, collectins, 
osteopontin, galectin 9, TLRs, complement fractions serum Amyloid-A, pancreatic stone protein/
regenerating protein, neopterin
Nucleic acids: micro-ribonucleic acid (miRNA), DNA methylation profi le
Other molecules:, LT antagonists, MAMPS, DAMPS 
Urine Proteic molecules: eosinophil protein X, bromotyrosine, lactate, taurine, trimethylamine N oxide 
(TMAO), myoinozitol, β2 micro-globulin 
Lipidic derivates: Cys-LT- LTC4, LTD4, LTE4, PGD2, PGF2, F2- isoprostane, 8-hydroxyguanosine
tion rate, that the level of hs-CRP is signifi cantly higher 
during exacerbations than in stable asthmatics, and 
the treatment with inhaled corticosteroids may reduce 
hs-CRP values. [18]
Th e association with other conditions that induce low 
grade systemic infl ammation, such as anemia, obesity or 
malnutrition interferes with hs-CRP values. [19]
Hs – CRP levels are elevated for the pre-term infants with 
bronchopulmonary dysplasia and Ureaplasma spp. colo-
nization. [21] 
Biomarkers related with a certain subtype of disease, 
endotype or particular condition
Cytokines are small, soluble, molecules responsible for 
intercellular communication. In airway infl ammatory 
diseases, cytokines are produced by both residents cells 
as well as the infl ammatory cells recruited at the infl am-
mation site. Th ey have an important role in maintenance 
and prolongation of infl ammatory process.[3]
IL-interleukin, G-CSF- Granulocyte colony-stimulating 
factor, RANTES- regulated on activation, normal T cell 
expressed and secreted, NK- natural killer, HMGB1- 
high mobility group box type 1, Cys-LT- Cysteinyl 
leukotrienes, NO- nitric oxide, LT- leucotrien, PG- 
prostaglandin, TX-thromboxan, IgE- imunglobulin 
E, YKL-40- Chitinase-3-like protein 1, hs-CRP-highly 
sensitive C reactive protein,TLR-Toll-like receptor, 
MAMP- microbe-associated molecular pattern, DAMPs 
-Damage-associated molecular patterns 
Biomarkers that assess globally the infl ammation
Highly sensitive “C” reactive protein is elevated in patients 
with asthma, especially allergic asthma, COPD, cystic 
fi brosis highly related with stage and severity of the 
disease. Higher levels are associated with the decline of 
pulmonary function. [2,12,19]
Recent studies attest that there is a signifi cant positive 
correlation between the hs-CRP values and the exacerba-
Table 2. Types of interleukines and their connecti on with airway infl ammati on [3,15]
Type 
of interleukin Origin









IL-1α,β Macrophages, monocytes, 
lymphocites, neutrophils, 
fi broblasts
Induction of proinfl ammatory proteins,
Th 17 diff erentiation √ √ √
IL-2 CD4, CD8 activated cells, 
mast cells, NK
Proliferation of T and B cells, NK cells √ √
IL-3 Macrophages, mast cells, T 
cells, NK eosinophils
Activatory for eosinophils and 
basophils, diff erentiation of dendritic 
cells
√ √
IL-4 Basophils, eosinophils, 
mast cells, NK cells,Th 2 
cells
Diff erentiation of Th 2
Infl ammatory and tissue adhesion, IgE 
synthesis, eosinophil recruitment
√
IL-5 Eosinophils, mast cells, NK 
cells,Th 2 cells
Chemotactic for eosinophils, 
remodelling √
IL-6 Mast cells, eosinophils, 
Endothelial cells, 
fi broblasts, macrophages, 
monocytes
Induction of acute phase reactants
T and B diff etentiation √
IL-7 Epithelial cells, dendritic 
cells, monocytes, 
macrophages, B cells
Induction of proliferation of pre-B cells
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Il-8 Monocytes, eosinophils, 
lymphocites, neutrophils
Chemoattractant for neutrophils, 
basophils, NK cells, T cells √
IL-9 Eosinophils, mast cells, 
Th 2,Th 9,Th 17
Growth factor for T cells and mast cells
Inhibition Th 1 cytokines
Stimulatory for mucus production
√
IL-10 Dendritic cells, 
macrophages, T and B cells
Imunosuppressive eff ect √ √
IL-11 Endothelial cells, epithelial 
cells, fi broblasts
Induction of acute phase proteins, 
chronic remodeling √
IL-12 Dendritic cells, 
neutrophils, macrophages, 
B cells
Development of Th 1
Activatory for NK cells
IL-13 Basophils, eosinophils, 
mast cells, T cells
Activator and recruitment for 
eosinophils √
IL-15 Macrophages, monocytes, 
T cells
T cell activation
Th 2 diff erentiation √
IL-16 Macrophages, monocytes, 
T cells
Modulatory for T cells responses √
IL-17A Th 17, NK cells Induction of proinfl ammatory cytokines √ √
Il-17B Mucosal epithelial cells, 
lung cells
Induction of proinfl ammatory cytokines √ √
IL-18 Macrophages, epithelial 
cells, dendritic cells
Promoting Th 1, Th 2 cell responses
IFN γ induction √
IL-21 Th 9, Th 17, NK cells Stimulatory for B cells proliferation
IL-22 Th 17, NK cells Tissue remodeling
IL-23 Macrophages, dendritic 
cells
Stimulatory for production of IL-17
Proliferation T cells, NK cells
IL-25 Eosinophils, Th 2 Induction Th 2
Inhibition for Th 1, Th 17
Stimulatory for IgE production
√
Il-27 Dendritic cells, epithelial 
cells, macrophages
Diff erentiation of Th 1
Inhibition of Th 17 √
IL-28 Dendritic cells Downregulation Th 2, upregulation Th 1 √
IL-31 Monocytes, mast cells Eosinophils production of IL-6, Il-8 √
Il-33 Epithelial cells, fi broblasts Induction Th 2 infl ammation
Proinfl ammatory cytokines release √
IL-36
IFN α, β Dendritic cells, nucleated 
cells
Activation T cells √
IFN γ Macrophages, NK cells, T 
and B cells
Th  1 diff erentiation √
TGF-β Various cells Balance of proinfl ammatory and 
antiinfl ammatory actions
Imuntolerance
TNF-α Macrophages, monocites, T 
and B cells, mast cells
Both proinfl ammatory (strong host 




Th e immune response can be divided in type 1 and type 
2 and has in the center the CD4+ T- T helper 1 (Th 1) and 
T helper 2 (Th 2) cell. Th 1 cells produce IL-2 and IFNγ 
being responsible by the type 1 immune response, and 
Th 2 cells secrete IL-4, IL-5 and IL-13, responsible for 
type 2 immunity. Eosinophilia and high antibody titres 
characterize type 2 immunity. [10]
In asthmatic infl ammation there is a Th 1/Th 2 imbalance, 
predominantly Th 2, and probably a relative Th 1 cyto-
kine production defi cit, which will direct the immune 
response by proinfl ammatory cytokines that stimulate 
the synthesis of IgE and eosinophils (IL-5). [14,30]
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Figure 1. Lymphocite T polarizati on: type 1 and type 2 immune responses
induced by IL-13. DPP4 is composed of 766 amino 
acid residues, and is found in both structural cells in 
their membrane and as a soluble protein in the blood.
[27] Although the role in asthma is not yet comple-
tely elucidated, it seems to have a stimulating role in 
proliferation of bronchial smooth muscle cells and 
lung fi broblasts. [15] DPP-4 regulates immunological 
pathways in asthma. Th ere is evidence that DDP-4 
can be used as a surrogate marker for aspirin-exa-
cerbated asthma. [15,26] Recent studies show that 
increased serum DPP-4 levels predicted a benefi cial 
response to tralokinumab (anti-IL-13 monoclonal 
antibody). [7]
– Osteopontin – cytokine having the extracellular 
matrix, most the immune system cells and struc-
tural cells as source is found to be elevated in both 
serum and bronchoalveolar lavage fl uid in asthmatic 
patients. Th is molecule is upregulated in the tissue 
of the bronchi of asthmatics, being related to basal 
membrane thickness. [28]
– VEGF- vascular endothelial growth factor – has 
elevated expression in the airways of asthmatic pati-
ents, responsible for the reduction of the caliber and 
has high levels in sputum. [28]
– HMGB1 – high mobility group box type 1-group of 
proteins from the alarmins family, a highly conserved 
DNA-binding protein, is one important dama-
ge-associated molecular pattern (DAMP), acting as 
a “danger signal”, responsible for both the initiation 
and perpetuance of the immune responses. HMGB1 
is produced by dendritic cells, NK, macrophages and 
released by nectrotic cells. [16] HMGB1 interacts with 
DNA and histones to determine chromatin structure 
and regulate key processes such as transcription [17], 
upregulates the synthesis of infl ammatory cytokines, 
chemotaxis of infl ammatory cells, being associated 
with acute and chronic infl ammation, immune and 
infl ammatory diseases, such as rheumatoid arthritis, 
myositis, scleroderma, systemic lupus erythematosus, 
Sjogren syndrome or ankylosing spondylitis. [17]. 
HMGB1 is implicated in the pathogenesis of asthma, 
Th erefore, asthma biomarkers can be divided into 
biomarkers related with type 2 asthma and eosinophilic 
infl ammation and non-type 2 asthma. 
Biomarkers related with type 2 asthma:
– Eosinophils continue to be a valuable biomarker 
for asthma as a risk factor, severity marker and as 
an indicator for disease control. Eosinophils can be 
determined in both sputum and blood. Th e controller 
medication, especially ICS, can be assessed by evalu-
ating the sputum and blood eosinophilia- persis-
tence of peripheral blood eosinophils indicating that 
anti-IL-5 therapy can be eff ective. Th e relation with 
asthma exacerbations is not yet totally defi ned, the 
sputum eosinophilia appears to be more predictable 
for exacerbation, comparing to blood eosinophilia. 
[5] Some surface biomarkers have been directly corre-
lated with severe asthma: CD13, CD25, CD29,CD32, 
CD44 and eosinophilic TGFβ expression.[28]
– Interleukins such as IL-4, IL-5, IL-10, IL-13 have high 
levels in sputum and serum. In a recent research, 
Agache I. and colleagues proposed a combination of 
biomarkers- IL-5, IL-13 as “best predictor for blood 
eosinophilia in adult asthmatics”.[1]
– Periostin – protein encoded by a gene induced by IL-4 
and IL-13 is a marker of type 2 immune response and 
therefore can be used as a biomarker for Th 2 asth-
matic phenotypes along with IL-13. High levels of 
periostin were found in bronchoalveolar lavage fl uid, 
having as a source the epithelial cells of the airways. 
[5] It is involved in the amplifi cation and extension 
of chronic infl ammation, recruitment and tissue 
infi ltration by eosinophils. [15,28]Th e limitations in 
the use of periostin are related to the other sources 
such as osteoblasts and tumors, nevertheless it can be 
considered as a surrogate marker not only for type 
2 immunity, but also for the assessment of of treat-
ments targeting IgE and IL-13. [5,15]
– Dipeptidyl peptidase 4 (DDP-4, adenosine deaminase 
complexing protein 2, CD26) is a glycoprotein with a 
molecular weight of 110 kDa encoded by DPP4 gene 
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inducing peribronchial collagen deposition. [9] 
Recent studies show that HMGB1 positively related 
to total serum IgE in children with asthma. [16]
Biomarkers correlated with non type 2 asthma:
– Cellular biomarkers are neutrophils and paucigranu-
locytic pattern. [5]
– Interleukins – IL-8, IL-12, IL-17, IL-18, IL-32 are asso-
ciated with non type2 asthma. Among them, IL-17 
have prognostic value for asthma severity. [1] IL-17 
is produced by activated CD4+ T cells – the Th 17 
cell lineage, along with IL-6, IL-17F, IL-22, αTNF. 
IL-17 and IL-17F can induce lung structural cells to 
secrete proinfl ammatory cytokines. IL-17 expression 
is increased in the lung, sputum, bronchoalveolar 
lavage fl uid (BALF), and serum of asthmatics. IL-17 
has an important therapeutic role- the presence of 
Th 17 cells may be responsible for the steroid insensiti-
vity due to uncontrolled IL-17 infl ammation induced 
by progressive doses of steroids. Recent studies show 
that a IL-17A contributes to airway fi brosis in asthma 
due to profi brotic cytokines, proangiogenic factors, 
and collagen production and also IL-17, promote 
airway smooth muscle cell proliferation and migra-
tion. [6]
Cystic fi brosis (CF) 
Cystic fi brosis is a recessive genetic exocrine disorder 
caused by mutations aff ecting the cystic fi brosis trans-
membrane conductance regulator (CFTR). Th e most 
common mutation is the deletion of a phenylalanine at 
position 508 on chromosome 7, but there are over 2000 
CFTR mutations.
In cystic fi brosis the biomarkers follow more than one 
direction: biomarkers of infection, biomarkers if infl am-
mation, biomarkers for therapy assessment. [22]
Biomarkers of infl ammation in cystic fi brosis demon-
strate the neutrophilic infl ammation which is the hall-
mark of the disease:
– Neutrophils accumulate in the airways of cystic 
fi brosis patients, playing a key role in the pathoge-
nesis of the disease. Th e excess of neutrophils drive 
a normal and salutary immune process, ment to 
defend the host, towards a pathological one. Besides 
the neutrophils accumulated, a lot of neutrophic 
products IL‐8, LTB4, C5a, IL‐17 are found at the 
infl ammatory site which contribute to the chemo-
taxis of new neutrophils. Th e clearance of these cells 
is defective in cystic fi brosis. Among the neutrophilic 
products, serine proteases: elastase, cathepsin G, and 
proteinase‐3, have an important role. Th e proteases 
released at high concentrations in the airway over-
load natural defense systems, induce the histological 
changes of the airway walls: disrupting tight junctions 
between epithelial cells, destruction of elastin, bron-
chiectasis, impaired mucociliary clearance. [23]
– Cytokines such as the proinfammatory interleukins: 
IL-1β, IL-6, IL-8, IL-17, IL‐33 have high concentra-
tions in the airways of patients with cystic fi brosis, 
being responsible for the attraction of neutrophils at 
the site of infl ammation. Th ey stimulate acute phase 
responses, induce cachexia and muscle catabolism. 
On the other hand, in cystic fi brosis, the airways lack 
some counter-regulatory molecules, such as IL-10 and 
nitric oxide. All these factors contribute to the status 
of chronic infl ammation present in the disease. [23]
– Neutrophil elastase (NE) – a very valuable sputum 
biomarker capable to monitor CF lung disease- 
correlating with bronchiectasis, with the ability 
to predict the lung function decline. It is related to 
pulmonary exacerbations, predicting time to next 
exacerbation and can off er data relating the response 
to the treatment. Other sputum biomarkers found in 
CF are calprotectin, myeloperoxidase, high-mobi-
lity group box 1 (HMGB-1) and YKL-40. [22] High 
mobility group box 1 (HMGB1) levels in sputum may 
predict future exacerbation. Recent studies, – Sagel 
and colleagues – demonstrated a strong association 
between sputum neutrophil elastase levels and the 
high velocity in the decline of the lung function. [24]
– Systemic infl ammatory biomarkers are serum C 
reactive protein (CRP), serum amyloid A (SAA) 
and calprotectin, neutrophil elastase antiprotease 
complexes (NEAPC), IL-6. CRP brings no valuable 
information on the severity of exacerbation when 
compared to clinical scoring. IL-8 and neutro-
phil elastase antiprotease complexes at the onset of 
exacerbation were associated with increased response 
to therapy, calprotectin is a superior biomarker for 
exacerbation than CRP. Serum calprotectin levels are 
signifi cantly associated with pulmonary exacerba-
tions and lung function decline in patients with cystic 
fi brosis [13,20,22,24]
Bronchopulmonary dysplasia
Th e development of the lung takes place in several stages: 
embryonic, pseudoglandular, canalicular, saccular and 
alveolar. Premature birth leads to disruption of lung 
development in the saccular stage. Th e fi nal stage in 
the development is the alveolar and vascular growth, 
requiring a complex network of signals, involving VEGF 
(vascular endothelial growth factor) and nitric oxide 
synthesis from the endothelium. [25]
Genetic and environmental factors act together on 
immature lung in its development leading to infl amma-
tion which is one of the main features of bronchopulmo-
nary dysplasia. [4] Some other factors participate, such 
as infection, injurious factor associated with mechanical 
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Th e immune dysregulation can be proven by decreased 
expression of CD62L on CD4 T cells, suggestive for their 
activation, while CD54 has an increased expression. [4]
Biomarkers of bronchopulmonary dysplasia
– Cytokines- oxidation and cellular damage are respon-
sible for the production of pro-infl ammatory cyto-
kines, such as IL-1β, IL-6, IL-8. Th ese interleukins 
have high levels in broncho-alveolar lavage fl uid, 
along with macrophages infl ammation proteins and 
monocyte chemoattractant proteins.[4,25] 
– VEGF- altered levels of VEGF constitutes a risk factor 
for bronchopulmonary dysplasia. [25]
– Endostatin is a molecule derived from collagen, an 
inhibitor of angiogenesis and an antagonist of VEGF, 
therefore aggressive for the lung. Studies demon-
strated high levels of endostatin in the lung of very 
low birth weight infants who developd bronchopul-
monary dysplasia.[25]
– Endothelin-1 is a endogenous vasoconstrictor, with 
pro-infl ammatory actions. High levels of endo-
thelin-1 were demonstrated in the lung of infants 
with bronchopulmonary dysplasia. [25]
– Th e maternal blood can serve as a source of biomar-
kers for the infant. High levels of alpha-fetoprotein, 
human chorionic gonadothrophin and unconjugated 
estriol are associated with higher risk for bronchopul-
monary dysplasia in the newborn [25] 
Conclusion
For airway infl ammation many biomarkers are useful. 
Some defi ne the disease as a whole, some are defi ning for 
certain aspects or endotypes. Th ere is no ideal biomarker 
for every disease. Th e winning combination proposed by 
many authors appears to be a panel of biomarkers which 
captures as many aspects as possible for each entity, but 
is usually diffi  cult to fi nd. 
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